Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This trial is designed to explore a modified dose and schedule of azacitidine in order to
more effectively address the needs of patients with low-risk myelodysplastic syndromes (MDS),
i.e., to alter the natural history of the disease without excessive toxicity or burden. The
administration of erythropoietin is designed to influence the differentiation of primitive
hematopoietic cells in which azacitidine has reversed the abnormal phenotype to red blood
cells for patients in whom inadequate production of red blood cells is the major clinical
issue.
Phase:
Phase 2
Details
Lead Sponsor:
Larry Cripe, MD
Collaborators:
Celgene Corporation Ortho Biotech Clinical Affairs, L.L.C. Walther Cancer Institute